A Phase II, Open Label Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa
Phase of Trial: Phase II
Latest Information Update: 28 Jan 2019
At a glance
- Drugs Bermekimab (Primary)
- Indications Hidradenitis suppurativa
- Focus Adverse reactions
- Sponsors XBiotech
- 28 Jan 2019 According to an XBiotech media release, data will be presented at the 2019 American Academy of Dermatology (AAD) annual meeting.
- 23 Jan 2019 According to a XBiotech media release, Dr. Alice Gottlieb, M.D., Ph.D., (Clinical Professor of Dermatology, Department of Dermatology, Icahn School of Medicine at Mount Sinai, NY, NY) is the the Chair of this study.
- 23 Jan 2019 Results (n=42) presented in a XBiotech media release.